

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bao Pharmaceuticals Co., Ltd.

上海寶濟藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2659)

VOLUNTARY ANNOUNCEMENT

IND for Subcutaneous Infusion of BJ007 for Injection (SC) was Approved by U.S. FDA

This announcement is made by Shanghai Bao Pharmaceuticals Co., Ltd. (上海寶濟藥業股份有限公司) (the “**Company**”) to provide its shareholders and potential investors with information in relation to the latest development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on May 27, 2026, the investigational new drug application (“**IND**”) for subcutaneous infusion of BJ007 for injection (SC), a product independently developed by the Company, was approved by the U.S. Food and Drug Administration (“**FDA**”), permitting the commencement of clinical trials.

The clinical trial approved this time is a randomized, open-label, clinical trial to evaluate the pharmacokinetic characteristics, absolute Bioavailability, and PK/PD efficacy of subcutaneous infusion of BJ007 for injection (SC) compared with intravenous infusion of Ceftriaxone Sodium for Injection (IV) in healthy trial participants.

About BJ007

BJ007 is a SC administered ceftriaxone sodium for the treatment of bacterial infections. To date, there are no approved SC administered ceftriaxone sodium globally, and BJ007 is the first and only drug candidate of this class advanced into clinical stage according to Frost & Sullivan.

Ceftriaxone sodium, a third-generation cephalosporin beta-lactam antibiotic, exerts bactericidal activity by binding to and inactivating penicillin-binding proteins (PBPs) on the bacterial cell wall. This disrupts the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, weakening bacterial cell wall and causing cell lysis. Ceftriaxone's time-dependent killing properties means that its effectiveness is primarily determined by the duration that the drug concentration remains above the minimum inhibitory concentration (MIC) required to inhibit bacterial growth. Ceftriaxone sodium is widely prescribed for a broad spectrum of bacterial infections, including lower respiratory tract infections, urinary tract and biliary tract infections due to susceptible bacteria, as well as gonorrhea, intra-abdominal infections, pelvic inflammatory disease, skin and soft tissue infections, bone and joint infections, bacteria sepsis, meningitis, and surgical prophylaxis.

While ceftriaxone sodium, typically administered intravenously, has been marketed globally for over 40 years with proven efficacy and safety in treating bacterial infections, patients with difficult venous access (DIVA) face challenges in receiving IV administration. Leveraging our large-volume SC delivery system powered by our Core Product recombinant human hyaluronidase, BJ007 is strategically developed to transform the IV infusion of currently available ceftriaxone sodium products into subcutaneous injection. The innovation reduces the need for vascular access and use of long-term IV catheters, providing a more convenient, safer and lower cost administration option. BJ007 can thus offer the non-inferior therapeutic benefits without the risks, discomfort and costs associated with infusion lines that are routinely required for longer courses of ceftriaxone treatment, while also overcoming key treatment challenges for DIVA patients.

We cannot guarantee that we will ultimately develop or commercialize BJ007 successfully. Considering several unpredictable factors in the process of clinical trials and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Bao Pharmaceuticals Co., Ltd.
上海寶濟藥業股份有限公司
Dr. LIU YANJUN
Chairman of the Board and Executive Director

Shanghai, PRC, June 10, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Liu Yanjun, Ms. Wang Zheng, Ms. Li Cui as executive Directors; (ii) Mr. Sun Yuhua as employee representative Director; (iii) Ms. Lin, Chia-ling, Mr. Diao Juanhuan and Mr. Li Chen as non-executive Directors; and (iv) Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen and Mr. Zhang Senquan as independent non-executive Directors.